Pasar al contenido principal

TERAPIAS PERSONALIZADAS EN CANCER DE PANCREAS

PID2021-124106OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Systemic Kras ablation disrupts myeloid cell homeostasis in adult mice

  • Zamorano-Dominguez, Elena
  • Morales-Cacho, Lucía
  • Barrero, Rebeca
  • Jiménez-Parrado, Silvia
  • Dhawahir, Alma
  • Hernández-Porras, Isabel
  • Simón-Carrasco, Lucía
  • Barrambana, Sara
  • Sun, Pian
  • Galván-Del-Rey, Ana
  • Rosas-Perez, Blanca
  • Liaki, Vasiliki
  • Drosten, Matthias
  • Musteanu, Mónica
  • Virga, Federico
  • Santos de Dios, Eugenio
  • Mulero, Francisca
  • Caleiras, Eduardo
  • Guerra, Carmen
  • Barbacid, Mariano
The KRAS oncogene has been associated with many types of cancer, including pancreatic, lung, and colorectal. For decades, its gene products were thought to be undruggable. However, during the last decade, a large battery of KRAS inhibitors selective against specific mutations (KRASG12C and KRASG12D), panKRAS inhibitors active against all KRAS isoforms, or even panRAS inhibitors, capable of inhibiting the three members of the RAS family, have been developed. In mice, the Kras locus is essential for embryonic development and can sustain adult homeostasis in the absence of Hras and Nras expression. Thus, we considered of interest to interrogate the role of the Kras locus in an experimental system to generate potentially relevant information regarding the use of panKRAS or panRAS inhibitors in the clinic. Here, we report that systemic ablation of Kras expression in adult mice does not induce significant changes in overall survival, body weight, glucose levels, metabolic profile, or heart function. In contrast, flow cytometry and histopathological analyses of organs such as blood, bone marrow, and spleen showed a significant increase of the myeloid lineage leading to myelomonocytic metaplasia. In this context, replacement of the KRAS isoforms by HRAS is sufficient to maintain adult homeostasis, suggesting that the unique properties of the Kras locus are primarily due to its pattern of expression rather than to the activity of its gene products., This work was supported by a research agreement between Mirati Therapeutics and Centro Nacional de Investigaciones Oncológicas. Additional funding was provided by the CRIS Cancer Foundation and the Agencia Estatal de Investigación (PID2021-124106OB-I00; MCIU/AEI/10.13039/501100011033). M.B. is a recipient of an Endowed Chair from the AXA Research Fund. C.G. and M.B. are recipients of a CIBERONC Fund (CB21/12/00121). F.V. was partially supported by International Postdoctoral Contracts “CNIO Friends” (2021) and by Juan de la Cierva Investigadores fellowship (JDC2022-048924-I) funded by MCIN/AEI/10.13039/501100011033 and Next GenerationEU/PRTR. E.Z.-D. is supported by an “Formación de Personal Investigador” (FPI) fellowship (PRE2022-102952) from the Spanish Ministry of Sciences and Innovation. L.M.-C. was supported by an “Formación del Profesorado Universitario” (FPU) fellowship from the Ministerio de Educación. S.B. is supported by a PhD scholarship from the Portuguese Foundation for Science and Technology (2021.05875.BD). V.L. was supported by an INPhINIT fellowship from the “la Caixa” Foundation (LCF/BQ/DI18/11660011) and a contract from the CRIS Cancer Foundation. A.G.-d.-R. is supported by an “Asociación Española Contra el Cáncer” (AECC) fellowship (PRDMA246123GALV). P.S. is partially supported by a fellowship from the China Scholarship Council., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance

  • Liaki, Vasiliki
  • Barrambana, Sara
  • Kostopoulou, Myrto
  • Lechuga, Carmen G
  • Zamorano-Dominguez, Elena
  • Acosta, Domingo
  • Morales-Cacho, Lucia
  • Álvarez, Ruth
  • Sun, Pian
  • Rosas-Perez, Blanca
  • Barrero, Rebeca
  • Jiménez-Parrado, Silvia
  • López-García, Alejandra
  • San Roman, Marta
  • López-Gil, Juan Carlos
  • Drosten, Matthias
  • Sainz, Bruno Jr.
  • Musteanu, Mónica
  • Caleiras, Eduardo
  • Dusetti, Nelson
  • Poli, Valeria
  • Sánchez-Bueno, Francisco
  • Guerra, Carmen
  • Barbacid, Mariano
Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest cancer survival rates. Recent studies using RAS inhibitors have opened the door to more efficacious therapies, although their beneficial effect is still limited mainly due to the rapid appearance of tumor resistance. Here, we demonstrate that genetic ablation of three independent nodes involved in downstream (RAF1), upstream (EGFR), and orthogonal (STAT3) KRAS signaling pathways leads to complete and permanent regression of orthotopic PDACs induced by KRAS/TP53 mutations. Likewise, a combination of selective inhibitors of KRAS (RMC-6236/daraxonrasib), EGFR family (afatinib), and STAT3 (SD36) induced the complete regression of orthotopic PDAC tumors with no evidence of tumor resistance for over 200 d posttreatment. This combination therapy also led to significant regression of genetically engineered mouse tumors as well as patient-derived tumor xenografts (PDX) in the absence of tumor relapses. Of importance, this combination therapy was well tolerated. In sum, these results should guide the development of new clinical trials that may benefit PDAC patients., This work was supported by grants from the CRIS Cancer Foundation, the European Research Council (ERC-AG/695566-THERACAN), the Agencia Estatal de Investigación cofunded with the European Regional Development Fund (ERDF-EU ERDF) (PID2021-124106OB-I00; MCIU/AEI/10.13039/501100011033), and the European Union “NextGenerationEU”/PRTR” (PLEC2022-009255;MCIU/AEI/10.13039/501100011033) to M.B. C.G. and M.B. are recipients of a CIBERONC Fund (CB21/12/00121). Additional funding included grants from the Instituto de Salud Carlos III cofunded by ERDF (PI19/00514), the “Carmen Delgado/Miguel Pérez Mateo Grants of the “Asociación Cancer de Páncreas” to C.G., the Italian Cancer Research Association (AIRC, IG16930), and the Italian Ministry of University and Research (MIUR PRIN 2017) to V.P. M.B. is the recipient of an Endowed Chair from the AXA Research Fund. V.L. was supported by an INPhINIT fellowship from “La Caixa” Foundation (LCF/BQ/DI18/11660011) and a contract from the CRIS Cancer Foundation. S.B. is supported by a PhD scholarship from the Foundation of Science and Technology of Portugal (10.54499/2021.05875.BD). M.K. was supported by an Erasmus+ scholarship for traineeship. L.M.-C. was supported by an FPU fellowship from the Ministerio de Educación. J.C.L-G. is supported by a postdoctoral fellowship from Amigos del CNIO, E.Z.-D. is supported by a FPI fellowship (PRE2022-102952) from the Spanish Ministry of Sciences and Innovation (PID2021-124106OB-I00). P.S. is partially supported by a fellowship from the China Scholarship Council., Peer reviewed